Evidence map›Paper›PMID 30460610›Full record

ArticleEuropean journal of nutrition2019

Hydroxytyrosol inhibits cancer stem cells and the metastatic capacity of triple-negative breast cancer cell lines by the simultaneous targeting of epithelial-to-mesenchymal transition, Wnt/β-catenin and TGFβ signaling pathways.

Marina Cruz-Lozano, Adrián González-González, Juan A Marchal, Esperanza Muñoz-Muela, Maria P Molina, Francisca E Cara, Anthony M Brown, Gerardo García-Rivas, Carmen Hernández-Brenes, Jose A Lorente and 3 more

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in European journal of nutrition, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
2.5field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 56 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 3 countries.

Marina Cruz-Lozano *UGC de Oncología Médica, Complejo Hospitalario de Jaén, Avenida del Ejército Español 10, Jaén, Spain.
Adrián González-González *UGC de Oncología Médica, Complejo Hospitalario de Jaén, Avenida del Ejército Español 10, Jaén, Spain.
Juan A MarchalInstituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Universidad de Granada, Granada, Spain.
Esperanza Muñoz-MuelaUGC de Oncología Médica, Complejo Hospitalario de Jaén, Avenida del Ejército Español 10, Jaén, Spain.
Maria P MolinaUGC de Oncología Médica, Complejo Hospitalario de Jaén, Avenida del Ejército Español 10, Jaén, Spain.
Francisca E CaraUGC de Oncología Médica, Complejo Hospitalario de Jaén, Avenida del Ejército Español 10, Jaén, Spain.
Anthony M BrownDepartment of Cell and Developmental Biology, Weill Cornell Medical College, New York, USA.
Gerardo García-RivasCentro de Investigación Biomédica, Hospital Zambrano Hellion, Tecnológico de Monterrey, Monterrey, NL, Mexico.
Carmen Hernández-BrenesCentro de Investigación Biomédica, Hospital Zambrano Hellion, Tecnológico de Monterrey, Monterrey, NL, Mexico.
Jose A LorenteGENYO. Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, PTS Granada -Avenida de la Ilustración, 114-18016, Granada, Spain.
Pedro Sanchez-RoviraUGC de Oncología Médica, Complejo Hospitalario de Jaén, Avenida del Ejército Español 10, Jaén, Spain.
Jenny C ChangHouston Methodist Cancer Center, Houston Methodist Hospital, Houston, TX, USA.
Sergio Granados-PrincipalUGC de Oncología Médica, Complejo Hospitalario de Jaén, Avenida del Ejército Español 10, Jaén, Spain. sergio.granados.exts@juntadeandalucia.es.ORCID http://orcid.org/0000-0001-8773-9489
Complejo Hospitalario de Jaén · ESHospital Zambrano Hellion · MXCornell University · USMethodist Hospital · USPfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research · ESUniversidad de Granada · ES

Funding

Instituto de Salud Carlos III CP14/00197Instituto de Salud Carlos III PI15/00336Instituto de Salud Carlos III PIE16/00045
6 · The paper itself

Abstract

purposeThis study was aimed to determine the impact of hydroxytyrosol (HT), a minor compound found in olive oil, on breast cancer stem cells (BCSCs) and the migration capacity of triple-negative breast cancer (TNBC) cell lines through the alteration of epithelial-to-mesenchymal transition (EMT) and embryonic signaling pathways.

methodsBCSCs self-renewal was determined by the mammosphere-forming efficiency in SUM159PT, BT549, MDA-MB-231 and Hs578T TNBC cell lines. Flow cytometric analysis of CD44

resultsHT reduced BCSCs self-renewal, ALDH

conclusionIn conclusion, we report for the first time the inhibitory role of HT on BCSCs and tumor cell migration by targeting EMT, Wnt/β-catenin and TGFβ signaling pathways. Our findings highlight the importance of the chemopreventive compound HT as a novel candidate to be investigated as an alternative targeted therapy for TNBC.

Indexed as

Antioxidantsbeta CateninBlotting, WesternEpithelial-Mesenchymal TransitionFlow CytometryHumansNeoplastic Stem CellsPhenylethyl AlcoholTransforming Growth Factor betaTriple Negative Breast NeoplasmsTumor Cells, CulturedWnt Signaling Pathway3,4-dihydroxyphenylethanolAntioxidantsbeta CateninPhenylethyl AlcoholTransforming Growth Factor betaCancer stem cellsEpithelial-to-mesenchymal transitionHydroxytyrosolOlive oilTriple-negative breast cancer

Identifiers

PMID30460610
OpenAlexW2900808021

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.